Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer Screening
By Robin Foster HealthDay Reporter
TUESDAY, Dec. 10, 2024 -- In guidelines that may encourage more women to get screened for cervical cancer, a leading health task force has backed giving women over 30 the option to collect their own vaginal samples for testing.
Instead of needing to have a complete pelvic exam, these women can now go to a doctor’s office and collect their own tissue to be tested for human papillomavirus (HPV), the infection that causes almost all cases of cervical cancer, say new guidelines issued on Tuesday by the U.S. Preventive Services Task Force.
Women can now use a swab to collect their own HPV samples, the task force said, because studies have shown self-collection is as accurate as when the tissue sample is collected by a clinician and it is proven to increase screening.
“Women who would be more comfortable collecting their HPV test sample themselves can now do so,” task force member Dr. Esa Davis said in a news release announcing the new guidance. “We hope that this new, effective option helps even more women get screened regularly.”
Experts noted that any efforts to get more women screened would be welcomed.
“What we worry about, as doctors who take care of women with cervical cancer, is that if screening becomes less routine, people kind of forget to do it,” Dr. Karen Lu, physician-in-chief of Moffitt Cancer Center in Tampa, Fla., told the New York Times.
The latest guidance follows the U.S. Food and Drug Administration's approval of a self-testing kit for cervical cancer last May. That test should be repeated every five years from age 30 until 65, when most women can stop screening, the task force added.
For those 30 and older, other screening options include Pap tests every three years, or a combined Pap smear and HPV test every five years, the task force noted. Still, an HPV test every five years is the ideal screening regimen.
The guideline change was issued amid growing concern over a drop in cancer screenings and confusion over cervical cancer testing regimens.
“It’s important to emphasize that cervical cancer is one of the most treatable and preventable types of cancer,” because screening is so effective, said Dr. John Wong, vice chair of the task force.
Most women who develop cervical cancer are those who have not been getting regular screening, the Times reported. About one-quarter of women aged 21 to 65 were not up-to-date on their cervical cancer screenings in 2021, according to the U.S. Centers for Disease Control and Prevention.
Cervical cancer kills 350,000 women annually around the globe. However, incidence fell dramatically in the United States over the last five decades. Between 1975 and 2022, to 6.8 cervical cancer cases per 100,000 women per year were 6.8 cases in 2022 compared to 13.9 cases per 100,000 women each year in 1975, the Times reported. Pap smears fueled much of that decline.
This year, the American Cancer Society (ACS) estimates that 13,820 new cases of invasive cervical cancer will be diagnosed and that about 4,360 women will die of the disease.
The ACS guidelines on cervical cancer screening emphasize that “the most important thing to remember is to get screened regularly, no matter which test you get.”
Women can stop screening at age 65 as long as they have had a history of normal test results from the past three Pap smears or their last two HPV tests.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-11 06:00
Read more
- Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
- Insurer Anthem Rescinds Anesthesia Policy Change After Backlash
- Grandparents & Grandkids: Poll Shows Them Helping Each Other
- Almost a Third of U.S. Retail Pharmacies Have Closed Since 2010
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
- Guidelines Developed for Treatment of Restless Legs Syndrome
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions